Vitamin D-Dependent Rickets Type 1B (VDDR1B) — Comprehensive Research Report

1. Disease Information

Overview. Vitamin D-dependent rickets type 1B (VDDR1B), also called vitamin D 25-hydroxylase deficiency or "selective 25-hydroxyvitamin D deficiency," is an autosomal recessive inborn error of vitamin D metabolism caused by loss-of-function variants in CYP2R1, which encodes the principal hepatic microsomal vitamin D 25-hydroxylase (Cheng et al., PNAS 2004, PMID:15128933). Loss of this enzyme activity blocks the first obligatory activation step of vitamin D — hydroxylation of vitamin D3/D2 at carbon-25 to form 25-hydroxyvitamin D [25(OH)D] — producing a phenotype that is clinically and radiographically indistinguishable from nutritional vitamin D deficiency rickets but that fails to respond, or responds only poorly, to conventional-dose vitamin D3 supplementation (Molin et al., J Bone Miner Res 2017, PMID:28548312).

Key identifiers: - OMIM: #600081 (VDDR1B, phenotype); 608713 (CYP2R1, gene) - MONDO: MONDO:0010810 - Gene: CYP2R1 (HGNC:20586), chromosome 11p15.2 - Orphanet: ORPHA:289320 (Vitamin D-dependent rickets type 1B) - ICD-10: E55.0 (Rickets, active) is used generically; no VDDR1B-specific code exists - MeSH:* Rickets (D012279); Vitamin D Deficiency (D014808)

Synonyms: 25-hydroxylase deficiency rickets; vitamin D 25-hydroxylase deficiency; selective 25-hydroxyvitamin D deficiency; CYP2R1 deficiency rickets; hereditary vitamin D-resistant rickets type 1B (this last term is discouraged since VDDR1B is not a vitamin-D-resistant disorder but a synthesis defect).

Data provenance: Essentially all published knowledge derives from individual patient/family case reports and small case series (the largest being 27 subjects from 9 Saudi families; Alzahrani et al. 2021, PMID:34137732), rather than population/aggregate registries — VDDR1B is exceedingly rare, with fewer than 40 molecularly confirmed patients reported worldwide as of 2024.

2. Etiology

Disease Causal Factors

VDDR1B is monogenic: biallelic (homozygous or compound heterozygous) loss-of-function variants in CYP2R1 abolish or severely reduce hepatic 25-hydroxylase activity (Cheng et al. 2004, PMID:15128933; Thacher et al., JCEM 2015, PMID:25942481). A subset of reported heterozygous carriers also show a milder, incompletely penetrant biochemical phenotype (blunted 25(OH)D response to vitamin D3 loading), suggesting semi-dominant/haploinsufficiency effects for some alleles (Thacher et al. 2015, PMID:25942481).

Genetic Risk Factors

Reported pathogenic variants (all in CYP2R1, NM_024514): - p.Leu99Pro (L99P, c.296T>C) — the most recurrent pathogenic allele, first reported homozygous in a Nigerian child (Cheng et al. 2004) and subsequently in Moroccan and additional Nigerian families (homozygous in 3, heterozygous in 6, across 2 generations of 2 Nigerian families; Thacher et al. 2015, PMID:25942481; Molin et al. 2017, PMID:28548312). In vitro expression shows normal protein levels but essentially abolished 25-hydroxylase activity. - p.Lys242Asn (K242N) — identified in a second Nigerian family; markedly reduced (not abolished) enzymatic activity in vitro (Thacher et al. 2015, PMID:25942481). - c.367+1G>A (splice donor) and c.768dupT (frameshift) — the two founder-like alleles accounting for the majority of the 27 Saudi Arabian patients from 9 families (12/27 and 15/27 patients respectively; 18 homozygous, 9 heterozygous carriers with biochemical abnormalities) (Alzahrani et al. 2021, PMID:34137732; earlier reported by Al Mutair et al., JCEM 2012, PMID:22855339, as compound heterozygous splice-site + frameshift mutations in a Saudi sibship). - Deletion/insertion (indel) mutation — homozygous in a French family reported by Molin et al. 2017 (PMID:28548312), alongside the recurrent L99P allele in a Moroccan family (7 patients, 2 families total). - c.50_51insTCGGCGGCGC (p.Leu18ArgfsTer79) — a novel frameshift variant, homozygous, reported in two siblings from India — the first molecularly confirmed VDDR1B case from Asia (JCEM Case Reports 2024, PMID:38440125). - Additional novel missense and truncating variants have been reported in isolated case reports through 2021 ("New Variants of the CYP2R1 Gene…", PMC8699237).

Population/allele frequency: Because reported alleles are private or regionally clustered (Nigeria, Saudi Arabia/Gulf, Morocco, France, India), none reach appreciable frequency in gnomAD; most pathogenic alleles are absent or present only as rare heterozygotes in population reference databases, consistent with a fully penetrant recessive Mendelian disease.

Environmental Risk Factors

No independent environmental cause exists for VDDR1B itself (it is monogenic), but the biochemical/clinical severity is strongly modulated by cutaneous vitamin D3 synthesis (sun exposure) and dietary vitamin D intake — because CYP2R1-null patients still retain a minor, CYP2R1-independent route of 25-hydroxylation (via CYP27A1 and other hepatic/extrahepatic P450s), higher substrate (vitamin D3) availability can partially compensate. This is the biochemical rationale for supraphysiologic vitamin D3 dosing as first-line therapy, and it is also why the phenotype can be misdiagnosed as ordinary nutritional rickets when a family history or lack of vitamin D3-dose response is not recognized (Molin et al. 2017, PMID:28548312 — explicitly framed as "a rare condition or a misdiagnosed condition").

Protective Factors

No specific genetic protective alleles have been described for VDDR1B. High cutaneous/dietary vitamin D3 substrate supply is the main modifiable factor mitigating severity, since residual (non-CYP2R1) 25-hydroxylase activity is substrate-driven.

Gene-Environment Interactions

The core gene-environment interaction is substrate-dependent enzymatic bypass: because a second, lower-affinity/lower-capacity 25-hydroxylation pathway exists (demonstrated definitively in Cyp2r1-knockout mice, which retain ~50% of normal serum 25(OH)D3 rather than none; Zhu et al., PNAS 2013, PMID:24019477), increasing vitamin D3 intake to supraphysiologic levels can drive meaningful 25(OH)D production even in the near-total absence of CYP2R1 activity. Homozygous L99P patients show a markedly blunted (but not entirely absent) rise in 25(OH)D after oral vitamin D3 loading compared with heterozygotes (Thacher et al. 2015, PMID:25942481), directly demonstrating gene-dose/substrate interaction.

3. Phenotypes

Characteristics: - Onset: Predominantly infantile/early childhood, though several reported cases (Nigerian kindred, Molin et al. 2017 French/Moroccan families) presented in later childhood/adolescence with milder or slowly progressive disease, and at least one adult cohort has been studied for long-term skeletal consequences (Wiedemann et al., Calcif Tissue Int 2020, PMID:32430692). - Severity/course: Variable — homozygotes for null alleles (e.g., L99P homozygotes) show more severe biochemical deficiency and more blunted treatment response than heterozygotes; disease is generally described as progressive if untreated, but non-progressive/stable once adequately treated with high-dose vitamin D3. - Frequency of individual phenotypes: Given the very small published cohorts (n≤27), only qualitative/case-count frequencies are available rather than validated percentage estimates; rickets, bowing, and biochemical hypovitaminosis D are near-universal among reported homozygotes, while seizures are less consistently reported. - Quality of life: Not systematically studied with validated instruments (no EQ-5D/SF-36/PROMIS data identified in the literature); qualitatively, adequately treated patients show good clinical/radiographic recovery ("rickets heal" — Thacher et al. 2015), and Wiedemann et al. 2020 (PMID:32430692) specifically found that prolonged 25-OH-vitamin D deficiency in treated adults did not impair bone mineral density, suggesting a favorable long-term skeletal prognosis with treatment.

4. Genetic/Molecular Information

Causal gene: CYP2R1 (cytochrome P450, family 2, subfamily R, polypeptide 1), HGNC:20586, OMIM *608713, chromosome 11p15.2. Encodes a microsomal (endoplasmic-reticulum-anchored) cytochrome P450 monooxygenase expressed predominantly in liver, with lower expression in numerous extrahepatic tissues (skin, testis, adipose, etc.).

Variant classification/type (per ACMG/AMP, as reported in the literature and ClinVar): - Missense: p.Leu99Pro (ClinVar RCV000002216, pathogenic), p.Lys242Asn - Frameshift: c.768dupT (p.Leu257Serfs*6; ClinVar VCV000977185), c.50_51insTCGGCGGCGC (p.Leu18ArgfsTer79) - Splice-site: c.367+1G>A (canonical splice-donor loss) - Indel: the French-family deletion/insertion reported by Molin et al. 2017

Functional consequences: In vitro heterologous expression studies (COS-7/HEK293 systems) show that pathogenic missense alleles (L99P) can retain normal protein expression levels while exhibiting complete loss of 25-hydroxylase catalytic activity, whereas K242N shows markedly reduced but not abolished activity — consistent with the somewhat milder phenotype variability seen clinically (Thacher et al. 2015, PMID:25942481). Frameshift/splice alleles are predicted to cause nonsense-mediated decay or truncated, non-functional protein (Al Mutair et al. 2012, PMID:22855339).

Allele frequency/population data: No pathogenic CYP2R1 allele associated with VDDR1B reaches polymorphic frequency in gnomAD/1000 Genomes/TOPMed; each is essentially private to the reporting family or regional cluster (Nigeria: L99P, K242N; Saudi Arabia: c.367+1G>A, c.768dupT; Morocco: L99P; France: indel; India: p.Leu18ArgfsTer79). This contrasts with common regulatory/coding CYP2R1 SNPs (e.g., rs10741657, rs2060793) that are well-studied GWAS hits for population variation in circulating 25(OH)D and are unrelated to the Mendelian disease.

Somatic vs. germline: Germline only; VDDR1B is not associated with somatic mosaicism or malignancy.

Modifier genes: None formally established; residual 25-hydroxylation via CYP27A1 and other minor hepatic/extrahepatic hydroxylases (demonstrated in the Cyp2r1/Cyp27a1 double-knockout mouse model — Zhu et al. 2013, PMID:24019477) functionally modifies phenotype severity but is not itself a defined "modifier gene" locus in humans.

Epigenetic information: Not disease-specific for VDDR1B; general regulatory studies show hepatic CYP2R1 expression is repressed by obesity/metabolic stress and streptozotocin-induced diabetes in mouse models (unrelated to the Mendelian disorder but relevant to acquired/relative 25(OH)D deficiency).

Chromosomal abnormalities: None reported; VDDR1B is caused by intragenic point/small indel variants, not large structural rearrangements.

Protein structure: The crystal structure of CYP2R1 in complex with vitamin D3 (Strushkevich et al., J Mol Biol 2008, PMID:18511070) shows the canonical CYP fold (12 core α-helices, β-sheet subdomains, heme buried centrally), a closed conformation with the substrate-access channel gated by the B′-helix, and vitamin D3 bound in an elongated pose with its aliphatic side chain oriented toward the heme iron for regiospecific C25 hydroxylation — explaining the enzyme's narrow substrate specificity and the structural basis by which active-site missense variants (e.g., L99P, which lies near a substrate-contacting region) abolish catalysis.

Suggested ontology terms: HGNC:20586 (CYP2R1); GO:0034653 (retinoic acid catabolic process — off-target; correct term: GO:0042359, vitamin D metabolic process); GO:0034644 (cellular response to UV); molecular function GO:0004497 (monooxygenase activity), GO:0070576 (vitamin D 25-hydroxylase activity, if available as a specific GO term); UniProt Q6VVW9 (mouse) / Q9UF56 (human CYP2R1); CHEBI:28934 (cholecalciferol/vitamin D3), CHEBI:17933 (25-hydroxyvitamin D3, calcifediol).

5. Environmental Information

• Environmental factors: Not disease-causing (VDDR1B is monogenic), but sunlight (UVB) exposure and dietary vitamin D intake determine substrate availability for the minor CYP2R1-independent 25-hydroxylation pathway and are the basis of the high-dose vitamin D3 treatment strategy.
• Lifestyle factors: Reduced sun exposure or low dietary vitamin D intake would be expected to unmask/worsen the phenotype in genetically predisposed individuals, though this has not been rigorously quantified for VDDR1B specifically (unlike common nutritional rickets).
• Infectious agents: None implicated.

6. Mechanism / Pathophysiology

Causal chain: 1. Initial defect (molecular/enzymatic): Biallelic loss-of-function CYP2R1 variants abolish or severely impair hepatic microsomal vitamin D 25-hydroxylase activity (GO:0004497 monooxygenase activity; the enzyme catalyzes NADPH-cytochrome P450 reductase-dependent hydroxylation at C25 of the vitamin D side chain). 2. Biochemical consequence: Failure to convert vitamin D3 (cholecalciferol, from skin/diet) to 25-hydroxyvitamin D3 [25(OH)D3, calcifediol] — the major circulating vitamin D metabolite and substrate for renal 1α-hydroxylase (CYP27B1). Serum 25(OH)D falls to deficient/near-undetectable levels despite normal or even excess vitamin D3 precursor availability (Cheng et al. 2004, PMID:15128933). 3. Downstream hormonal consequence: Reduced 25(OH)D substrate limits renal CYP27B1-mediated production of the active hormone 1,25-dihydroxyvitamin D3 [1,25(OH)2D3, calcitriol], though residual (non-CYP2R1) 25-hydroxylation and compensatory renal 1α-hydroxylase upregulation can partially buffer 1,25(OH)2D3 levels — hence 1,25(OH)2D3 may be low-normal rather than undetectable (distinguishing VDDR1B biochemically from the more profound calcitriol deficiency of VDDR1A/CYP27B1 deficiency). 4. Cellular/tissue consequence: Reduced calcitriol-VDR (vitamin D receptor, NR1I1) signaling in intestinal enterocytes decreases active transcellular calcium (and secondarily phosphate) absorption (biological process: GO:0070508, cholesterol import; more relevantly GO:0006816 calcium ion transport and GO:0030299 intestinal cholesterol absorption analogs — the specific relevant GO term is GO:0033280, response to vitamin D). 5. Systemic consequence — mineral homeostasis: Reduced intestinal calcium absorption → hypocalcemia → compensatory secondary hyperparathyroidism (elevated PTH) → renal phosphate wasting → hypophosphatemia, and PTH-driven increased bone turnover contributing to elevated serum alkaline phosphatase. 6. Tissue-level outcome — impaired mineralization: Combined hypocalcemia/hypophosphatemia impair hydroxyapatite deposition at the growth-plate mineralization front, producing the rachitic growth-plate histology (widened, disorganized hypertrophic chondrocyte zone) and osteomalacic changes in cortical/trabecular bone, manifesting clinically as rickets, bowing, rachitic rosary, and growth-plate widening.

Cell types involved (CL terms): hepatocyte (CL:0000182, site of primary enzymatic defect), enterocyte/intestinal absorptive cell (CL:0000584, target of reduced calcitriol signaling), chondrocyte — growth plate hypertrophic chondrocyte (CL:0000138, site of impaired mineralization), osteoblast (CL:0000062) and osteoclast (CL:0000092, bone remodeling/turnover), chief cell of parathyroid gland (CL:1000398, source of compensatory PTH secretion), and renal proximal tubule epithelial cell (CL:1001016, site of CYP27B1 1α-hydroxylation and, secondarily, PTH-driven phosphate wasting).

Anatomical/organ correlate: This causal chain maps directly onto dismech's defective_skeletal_mineralization module (the calciopenic arm — nutritional-vitamin-D-deficiency-analogous mechanism, converging on "Impaired Hydroxyapatite Deposition at the Mineralization Front") — VDDR1B is a strong candidate conformer to that module's calciopenic trigger arm, entering via a primary hepatic 25-hydroxylation defect rather than dietary/sunlight deficiency, but converging on the same rate-limiting mineralization node.

Molecular pathways (KEGG/Reactome): Vitamin D metabolism/activation pathway (Reactome R-HSA-5579022, "Defective CYP2R1 causes vitamin D 25-hydroxylase deficiency" — Reactome has a specific disease pathway entry for this defect); KEGG hsa00140 (Steroid hormone biosynthesis, vitamin D branch).

Immune involvement: Not a primary disease mechanism; VDR/calcitriol signaling has broader immunomodulatory roles described in the general vitamin D literature, but no VDDR1B-specific immune phenotype has been reported.

Molecular profiling / omics: No transcriptomic, proteomic, or single-cell studies specific to VDDR1B patient tissue have been published (the disease is studied almost exclusively via targeted Sanger/exome sequencing and biochemical phenotyping, not omics).

7. Anatomical Structures Affected

• Organ level (primary): Liver (site of CYP2R1 deficiency; UBERON:0002107); skeletal system broadly (rickets/osteomalacia).
• Organ level (secondary): Kidney (compensatory 1α-hydroxylase activity, renal phosphate wasting; UBERON:0002113); parathyroid glands (compensatory hyperplasia/hypersecretion; UBERON:0001132); small intestine (reduced calcium/phosphate absorption; UBERON:0002108).
• Body systems: Skeletal system, endocrine system (calcium-PTH-vitamin D axis), digestive system (hepatic and intestinal components).
• Tissue/cell level: Growth plate cartilage (UBERON:0002514) — hypertrophic chondrocyte zone; long bone cortical/trabecular bone (UBERON:0002481); hepatocyte microsomal/ER compartment (site of CYP2R1 localization).
• Subcellular level: Endoplasmic reticulum (GO:0005783) — CYP2R1 is an ER-membrane-anchored microsomal P450.
• Localization/laterality: Systemic/bilateral — rickets and bowing are bilateral, symmetric skeletal findings (unlike unilateral focal bone lesions).

8. Temporal Development

• Onset: Typically infancy to early childhood (as young as 2 years for radiographic bowing in the index Nigerian family), though later-childhood/adolescent presentation is also reported; onset pattern is insidious/chronic rather than acute.
• Progression: Untreated disease is progressive (worsening rachitic deformity, growth impairment); with high-dose vitamin D3 treatment, radiographic healing of rickets is documented (Thacher et al. 2015, PMID:25942481), and adult follow-up (Wiedemann et al. 2020, PMID:32430692) shows preserved bone mineral density despite persistent biochemical 25(OH)D deficiency — suggesting good long-term prognosis with adequate calcium/vitamin D3 management even if full biochemical normalization of 25(OH)D is not achieved.
• Disease course pattern: Chronic, lifelong biochemical defect (enzyme deficiency is permanent), but clinically manageable/stable with treatment; relapse on treatment discontinuation has been specifically described as a diagnostic clue distinguishing VDDR1B from self-limited nutritional rickets (JCEM Case Reports 2024, PMID:38440125).
• Critical periods: Growth-plate-open childhood/adolescence is the period of clinical vulnerability for rachitic skeletal deformity; after growth-plate closure, the primary residual risk shifts to osteomalacia/bone mineral density, which appears to be less severely affected in treated adults.

9. Inheritance and Population

• Epidemiology: No formal prevalence/incidence estimate exists; VDDR1B is classified as ultra-rare, with the world literature comprising fewer than ~40 molecularly confirmed cases across scattered case reports/small series as of 2024. This maps to prevalence_class: NOT_YET_DOCUMENTED or ULTRA_RARE in dismech terms, sourced from Orphanet (ORPHA:289320).
• Inheritance pattern: Autosomal recessive (biallelic homozygous or compound heterozygous variants). Notably, several reports describe heterozygous carriers with a milder, incompletely penetrant biochemical phenotype (subnormal 25(OH)D response to vitamin D3 challenge) — this is a semi-dominant/haploinsufficiency signal worth capturing explicitly (e.g., an Inheritance block noting incomplete penetrance in heterozygotes, distinct from the fully penetrant recessive homozygous/compound-heterozygous disease).
• Penetrance/expressivity: Homozygous null genotypes show high penetrance for biochemical and clinical rickets; expressivity is variable in severity and age of clinical recognition, likely modulated by sun exposure/diet (substrate availability) as discussed above.
• Consanguinity: Multiple reported kindreds (Nigerian, Saudi Arabian, Moroccan) are from populations/family structures with elevated consanguinity, consistent with recessive inheritance and founder alleles; the Saudi cohort (Alzahrani et al. 2021) specifically comprises 9 families with two recurrent founder-like alleles.
• Founder effects: L99P recurs across Nigerian and Moroccan families (possibly a mutational hotspot rather than a single founder haplotype, given geographic spread); c.367+1G>A and c.768dupT appear to function as regional founder/recurrent alleles within the Saudi Arabian cohort.
• Affected populations/geography: Cases reported from Nigeria, Saudi Arabia (largest series), Morocco, France, and — as of 2024 — India (first Asian case, JCEM Case Reports 2024, PMID:38440125), suggesting global but sporadic distribution rather than strict geographic restriction, with ascertainment likely biased toward regions/populations with active clinical genetics programs and higher consanguinity rates.
• Sex ratio / age distribution: No sex predilection has been reported; case series span pediatric through adult ages (Wiedemann et al. 2020 specifically studied adult outcomes).

10. Diagnostics

Clinical/laboratory tests: - Serum 25-hydroxyvitamin D (25(OH)D) — markedly low/undetectable despite adequate sun/dietary exposure (the key discriminating lab finding); LOINC 62292-8 (25-Hydroxyvitamin D3). - Serum calcium (low/low-normal), phosphate (low), alkaline phosphatase (elevated), intact PTH (elevated) — the classic secondary-hyperparathyroid rachitic biochemical panel. - Serum 1,25-dihydroxyvitamin D — typically low-normal (distinguishing from the profoundly low/undetectable 1,25(OH)2D of VDDR1A/CYP27B1 deficiency, where 25(OH)D is normal-to-high but 1α-hydroxylation is blocked). - Radiographic imaging (long bones, wrists, chest) — classic rachitic metaphyseal fraying/cupping, rib beading, bowing.

Genetic testing: - Targeted CYP2R1 Sanger sequencing or a rickets/metabolic-bone-disease gene panel is the recommended diagnostic approach once biochemical findings (low 25(OH)D unresponsive to standard vitamin D3 dosing, especially with a positive family history or parental consanguinity) raise suspicion. - Whole-exome sequencing has been used in several reported cases when the phenotype was initially misattributed to nutritional deficiency.

Clinical criteria / differential diagnosis: - Nutritional vitamin D deficiency rickets: distinguished by response to standard-dose vitamin D3 and correction of 25(OH)D; VDDR1B does not normalize 25(OH)D with usual doses and requires supraphysiologic dosing or fails to respond to repeated conventional courses (this non-response is the single most important clinical clue prompting genetic testing — emphasized in JCEM Case Reports 2024, PMID:38440125). - VDDR type 1A (CYP27B1 deficiency, OMIM #264700): 25(OH)D is normal-to-elevated but 1,25(OH)2D is low/undetectable (blocked renal 1α-hydroxylation), the inverse biochemical pattern from VDDR1B. - VDDR type 2A (VDR mutations, hereditary vitamin D-resistant rickets, OMIM #277440): elevated 1,25(OH)2D with target-organ resistance (often with alopecia). - VDDR type 3 (CYP3A4-mediated accelerated vitamin D inactivation, OMIM #619073): a distinct hypercatabolic mechanism. - Hypophosphatemic rickets (e.g., X-linked, PHEX/FGF23-mediated): distinguished by normal PTH and normal/high 1,25(OH)2D with isolated renal phosphate wasting, versus the secondary-hyperparathyroid picture of VDDR1B.

Screening: No population newborn or carrier screening program exists for VDDR1B given its extreme rarity; case-finding is clinical (family history of rickets, consanguinity, treatment non-response) followed by targeted sequencing.

11. Outcome/Prognosis

• Mortality: No disease-specific mortality has been reported; VDDR1B is not considered a life-limiting condition when diagnosed and treated.
• Morbidity: Untreated/undiagnosed disease carries morbidity from progressive skeletal deformity (bowing), growth impairment, and potentially hypocalcemic seizures in severe infantile presentations.
• Functional/skeletal outcome with treatment: Radiographic healing of rickets is well documented with high-dose vitamin D3 (Thacher et al. 2015, PMID:25942481; JCEM Case Reports 2024, PMID:38440125). Long-term adult follow-up (Wiedemann et al. 2020, PMID:32430692) found that persistent biochemical 25(OH)D deficiency, once patients are past the growth-plate-vulnerable period and on adequate calcium/vitamin D management, does not translate into reduced bone mineral density — a reassuring prognostic finding.
• Complications: Growth deformity/bowing if diagnosis is delayed; recurrence/relapse of rachitic biochemistry on treatment discontinuation is a recognized pattern used diagnostically.
• Prognostic factors: Genotype severity (null/frameshift/splice vs. hypomorphic missense such as K242N) correlates with degree of biochemical deficiency and blunting of treatment response; early diagnosis and sustained supraphysiologic vitamin D3/calcium therapy are the main modifiable prognostic levers.

12. Treatment

Pharmacotherapy (first-line): - High-dose (supraphysiologic) oral cholecalciferol (vitamin D3) plus calcium supplementation is the mainstay, with dose titrated against serum alkaline phosphatase, 25(OH)D, and PTH to achieve normalization and radiographic healing (JCEM Case Reports 2024, PMID:38440125; Thacher et al. 2015, PMID:25942481). NCIT term: NCIT:C15986 (Pharmacotherapy) as treatment_term, with therapeutic_agent CHEBI:28934 (cholecalciferol). - Calcifediol [25(OH)D3] supplementation is mechanistically attractive (it bypasses the defective hydroxylation step entirely) and has been used/discussed in the literature, though most published cases relied on high-dose native vitamin D3 with clinical/biochemical response, implying that some residual (CYP2R1-independent) 25-hydroxylation capacity is exploitable at high substrate doses. Where used, calcifediol would map to therapeutic_agent CHEBI:17933 (calcifediol/25-hydroxyvitamin D3) under the same NCIT:C15986 Pharmacotherapy treatment_term. - Calcitriol [1,25(OH)2D3] is a theoretical option (bypassing both defective hydroxylation steps) but is not the standard reported approach for VDDR1B specifically (contrast with VDDR1A, where calcitriol is first-line because the defect is downstream at the 1α-hydroxylation step).

Advanced therapeutics: No gene therapy, cell therapy, or RNA-based therapeutics have been developed or trialed for VDDR1B — the condition is effectively manageable with vitamin D3/calcium supplementation, which has limited the impetus for advanced modality development.

Surgical: Orthopedic correction (e.g., osteotomy) may be considered for severe, fixed bowing deformity that does not remodel after biochemical correction, as in other rachitic conditions, though this is not specifically documented in the VDDR1B literature reviewed.

Supportive care: Physical therapy/rehabilitation for gait or deformity-related functional impairment (NCIT:C15302, Physical Therapy) may be used adjunctively, per general rachitic-disease management, though not specifically reported for VDDR1B.

Monitoring/treatment strategy: Dose titration is driven by serial serum alkaline phosphatase, 25(OH)D, calcium, phosphate, and PTH, aiming for normalization of all markers and radiographic healing; because relapse occurs on treatment discontinuation, long-term/indefinite supplementation is implied rather than a time-limited course (JCEM Case Reports 2024, PMID:38440125).

Experimental treatments: No registered clinical trials (ClinicalTrials.gov) specific to VDDR1B were identified — consistent with its extreme rarity and effective management via existing vitamin D formulations.

Adverse events: Because supraphysiologic vitamin D3 dosing is used, monitoring for hypercalcemia/hypercalciuria and vitamin D toxicity is an implied but not separately quantified risk in the literature reviewed.

13. Prevention

• Primary prevention: Not applicable in the classic sense (monogenic recessive disease); genetic counseling for consanguineous families or those with an affected child is the relevant preventive intervention.
• Screening/early detection: Prenatal or carrier testing could theoretically be offered in families with a known pathogenic CYP2R1 variant, though no formal ACMG/professional-society screening recommendation specific to VDDR1B exists given its rarity.
• Genetic counseling: Recommended for identified families to inform recurrence risk (25% for future affected offspring of two carrier parents) and to guide early biochemical monitoring/prophylactic vitamin D3 dosing in at-risk siblings.
• Behavioral/public health: General population-level vitamin D sufficiency campaigns (sunlight exposure, dietary/supplement fortification) do not prevent VDDR1B itself, but adequate substrate availability mitigates severity in affected individuals and could plausibly delay/reduce clinical presentation.

14. Other Species / Natural Disease

• Taxonomy: No naturally occurring VDDR1B-equivalent disease has been reported in companion animals or wildlife (unlike some other Mendelian metabolic bone diseases with veterinary correlates). NCBITaxon:9606 (Homo sapiens) is the sole natural-disease species.
• Orthologous gene: Mouse Cyp2r1 (NCBI Gene: 74790) is the well-characterized ortholog used for functional/model studies (see below); Uniprot Q6VVW9 (mouse Cyp2r1).
• Comparative biology: CYP2R1's role as the principal vitamin D 25-hydroxylase is evolutionarily conserved across mammals, supporting cross-species mechanistic relevance of the mouse knockout data to human pathophysiology, though as detailed below the mouse model's phenotype is notably milder than the human disease (a HUMAN_MODEL_MISMATCH-relevant point for dismech curation).

15. Model Organisms

Mouse — Cyp2r1 knockout (global): Zhu, Ochalek, Kaufmann, Jones & DeLuca, PNAS 2013 (PMID:24019477), "CYP2R1 is a major, but not exclusive, contributor to 25-hydroxyvitamin D production in vivo." Cyp2r1⁻/⁻ mice show >50% reduction (not complete loss) in serum 25(OH)D3, with unchanged serum 1,25(OH)2D3 and no overt health/skeletal phenotype reported in the paper — i.e., the mouse model partially, not fully, recapitulates the human biochemical defect and does not reproduce the rachitic phenotype seen in human null patients. This is an important HUMAN_MODEL_MISMATCH/FAILS_TO_RECAPITULATE-relevant finding for dismech curation: the residual 25-hydroxylation capacity is proportionally much greater in mouse than appears to be the case in the most severely affected human homozygotes (e.g., L99P homozygotes with profound, blunted-response deficiency). - A double knockout of Cyp2r1 and Cyp27a1 (the latter encoding a mitochondrial P450 with minor 25-hydroxylase side activity) was also generated in the same study; circulating 25(OH)D3 and 1,25(OH)2D levels remained similar to the single Cyp2r1 knockout, indicating that additional, still-unidentified 25-hydroxylase(s) contribute to the residual activity — an open mechanistic gap explicitly flagged by the authors and relevant for a KNOWLEDGE_GAP discussion node in a dismech pathophysiology model (the identity of the "other" enzyme(s) responsible for the residual ~50% activity in Cyp2r1-null mice remains unresolved as of the cited literature). - Model limitations: The mild mouse phenotype (no overt rachitic bone disease reported) limits its use for studying skeletal/clinical endpoints of VDDR1B and suggests either species differences in the relative contribution of alternative hydroxylases, in dietary/husbandry vitamin D substrate availability, or in downstream calcium-handling compensation — none of which have been fully dissected in the literature reviewed. - Applications: The knockout mouse remains the primary tool for studying CYP2R1's biochemical/enzymological role in whole-organism vitamin D activation and for testing alternative-pathway hypotheses (e.g., candidate secondary 25-hydroxylases), but is not an adequate model for the severe/complete human null phenotype or its skeletal consequences. - Resources: MGI accession for Cyp2r1 (MGI:1919338); IMPC/KOMP repositories may hold additional Cyp2r1 allele lines beyond the specific knockout described by Zhu et al.

In vitro models: Heterologous expression systems (COS-7, HEK293, or yeast/insect-cell expression of recombinant CYP2R1) have been used extensively to functionally characterize individual patient variants (e.g., L99P, K242N) for residual enzymatic activity, as cited above (Thacher et al. 2015, PMID:25942481) — these represent the most direct and best-characterized "model" evidence linking specific human genotypes to loss/reduction of 25-hydroxylase catalytic function, complementing the whole-organism mouse data.

Summary Table of Key Evidence

Sources: - Novel Mutation in CYP2R1 Causing Vitamin D-Dependent Rickets Type 1b (JCEM Case Reports 2024) - OMIM #600081 – VITAMIN D HYDROXYLATION-DEFICIENT RICKETS, TYPE 1B - OMIM *608713 – CYP2R1 - Vitamin D–Dependent Rickets Type 1B: A Rare Condition or a Misdiagnosed Condition? (JBMR 2017) - 25-Hydroxylase vitamin D deficiency in 27 Saudi Arabian subjects (Endocrine Connections 2021) - Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase (PNAS 2004) - CYP2R1 is a major, but not exclusive, contributor to 25-hydroxyvitamin D production in vivo (PNAS 2013) - Mutation of the CYP2R1 vitamin D 25-hydroxylase in a Saudi Arabian family (2012) - CYP2R1 mutations causing vitamin D-deficiency rickets (review, 2017) - vitamin D hydroxylation-deficient rickets, type 1B – MONDO/NORD - Vitamin D Hydroxylation-Deficient Rickets, Type 1b – MalaCards - Structural Analysis of CYP2R1 in Complex with Vitamin D3 (J Mol Biol 2008) - New Variants of the CYP2R1 Gene in Individuals with Severe 25(OH)D Deficiency - Two novel CYP2R1 mutations in a family with vitamin D-dependent rickets type 1b (2021) - Prolonged 25-OH Vitamin D Deficiency Does Not Impair Bone Mineral Density in Adult Patients With CYP2R1 Deficiency (Calcif Tissue Int 2020) - ClinVar VCV000002216 – CYP2R1 c.296T>C (p.Leu99Pro) - ClinVar VCV000977185 – CYP2R1 c.768dupT

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.